Review article · 2024 · Open access
Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy
Biochemical Pharmacology, 232, 116685 · Published 28 November 2024 · DOI 10.1016/j.bcp.2024.116685
In brief
“Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy” is a 2024 review article by Sara Escalera-Anzola and 5 co-authors, published in Biochemical Pharmacology. OpenAlex counts 14 citations as of 21 November 2026, which puts it in the top 2% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Biochemical Pharmacology.
- Citations
- 14
- Most cited in
- 2025 (7)
- Field-weighted impact
- 0.31
- References
- 79
- Authors
- 6
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide, mainly due to its high heterogeneity, resistance to therapy and late diagnosis, with a 5-year survival rate of less than 10%. This dismal prognosis has promoted strategies to develop more effective treatments. Nanoparticle-based strategies have emerged, in the last decades, as a great opportunity because they can enhance drug delivery and promote controlled release, presenting lower side effects than conventional therapeutic regimens. Moreover, nanoparticles can often be modified to target specific cells or to achieve a sustained release of the drugs into the tumor. However, very few nanoparticle-based therapies are clinically approved. Concretely for pancreatic cancer treatment only two nanoformulations have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) so far. Clinical translation of nanoparticles remains a challenge for modern medicine, and in particular for pancreatic cancer therapy, because of the complexity of the disease, and a lack of studies been performed in clinically relevant in vitro and in vivo models. In this review, we have summarized the most recent clinical trials using nanoparticle-based formulations in PDAC, giving a small context of the diverse types of nanoparticles employed and the most recent advancements in the field.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Escalera-Anzola, S., Rosado, M., Yang, Y., Sánchez, D. P., Pedro-Liberal, C. S., & Acedo, P. (2024). Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy. Biochemical Pharmacology, 232, 116685. https://doi.org/10.1016/j.bcp.2024.116685
MLA 9
Escalera-Anzola, Sara, et al. “Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy.” Biochemical Pharmacology, vol. 232, 2024, p. 116685. https://doi.org/10.1016/j.bcp.2024.116685.
Chicago
Escalera-Anzola, Sara, Maria Rosado, Yuchen Yang, Daniel Parra Sánchez, Carolina San Pedro-Liberal, and Pilar Acedo. 2024. “Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy.” Biochemical Pharmacology 232: 116685. https://doi.org/10.1016/j.bcp.2024.116685.
Harvard
Escalera-Anzola, S. et al. (2024) ‘Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy’, Biochemical Pharmacology, 232, p. 116685. doi:10.1016/j.bcp.2024.116685.
IEEE
S. Escalera-Anzola, M. Rosado, Y. Yang, D. P. Sánchez, C. S. Pedro-Liberal, and P. Acedo, “Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy,” Biochemical Pharmacology, vol. 232, p. 116685, 2024, doi: 10.1016/j.bcp.2024.116685.
BibTeX
@article{escaleraanzola2024breakthroughs,
title = {{Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy}},
author = {Escalera-Anzola, Sara and Rosado, Maria and Yang, Yuchen and Sánchez, Daniel Parra and Pedro-Liberal, Carolina San and Acedo, Pilar},
journal = {Biochemical Pharmacology},
year = {2024},
volume = {232},
pages = {116685},
doi = {10.1016/j.bcp.2024.116685},
url = {https://doi.org/10.1016/j.bcp.2024.116685}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- pancreatic ductal adenocarcinoma
- nanoparticles
- nanoparticle drug delivery
- targeted drug delivery
- controlled drug release
- clinical trials
- nanoformulations
- clinical translation
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Escalera-Anzola, S., Rosado, M., Yang, Y., Sánchez, D. P., Pedro-Liberal, C. S., & Acedo, P. (2024). Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy. Biochemical Pharmacology, 232, 116685. https://doi.org/10.1016/j.bcp.2024.116685
How many times has this paper been cited?
14 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Biochemical Pharmacology: sign in and open the full text from this page.
Who wrote this paper?
Sara Escalera-Anzola, Maria Rosado, Yuchen Yang, Daniel Parra Sánchez, Carolina San Pedro-Liberal, Pilar Acedo.
What is the DOI of this paper?
10.1016/j.bcp.2024.116685, permanently at https://doi.org/10.1016/j.bcp.2024.116685. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.